Polygodial analog induces apoptosis in LNCaP prostate cancer cells

Area of Science:

• Oncology
• Pharmacology
• Medicinal Chemistry

Background:

• Prostate cancer (PCa) is a leading cause of cancer death in men, with limited effective chemotherapeutic options.
• Current treatments for PCa often lack efficacy and cause significant side effects, necessitating novel therapeutic strategies.
• Polygodial (PG), a natural compound, has shown potential, but synthetic analogs may offer improved therapeutic properties.

Purpose of the Study:

• To synthesize and evaluate the anti-cancer effects of a novel polygodial analog, DRP-27, on the LNCaP prostate cancer cell line.
• To investigate the underlying anti-cancer mechanisms of DRP-27 in preclinical models.
• To assess DRP-27's potential as a new chemotherapeutic agent for prostate cancer.

Main Methods:

• Cell viability was assessed using MTT assays.
• Anchorage-independent growth was measured via soft agar assays.
• Apoptosis, reactive oxygen species (ROS) generation, and molecular mechanisms were analyzed using Annexin-V, TUNEL, fluorescence assays, and Western blotting.

Main Results:

• DRP-27 significantly inhibited LNCaP cell proliferation and anchorage-independent growth in a dose-dependent manner.
• DRP-27 induced apoptosis and increased intracellular ROS levels in prostate cancer cells.
• Western blot analysis indicated DRP-27 downregulated survivin and upregulated Bax and pH2AX expression, suggesting DNA damage and apoptotic pathways activation.

Conclusions:

• The synthetic polygodial analog DRP-27 demonstrates potent anti-cancer activity against prostate cancer cells in vitro.
• DRP-27 induces apoptosis and activates cell death pathways, making it a potential candidate for further development as a PCa therapeutic.
• This study supports DRP-27 as a promising novel chemotherapeutic agent for prostate cancer treatment.